Ginsenoside Rb1 has potential for use as an anti-obesity therapeutic agent that modulates obesity-induced inflammation and improves central leptin sensitivity in HF diet-induced obesity. Here, LEP is linked to obesity due to melanocortin 4 receptor deficiency.